Meropenem was 8-to 32-fold more active (MIC for 90% of strains = 0.125 ,Ig/ml) than imipenem against a collection of Haemophilus influenzae strains characterized as either susceptible to ampicillin or resistant to that agent by virtue of 13-lactamase or nonenzymatic mechanisms. MBCs and kinetic kill curve tests showed that meropenem (as well as imipenem, several cephalosporins, and amoxicillin-clavulanate) was bactericidal against all strains at or within four times the respective MICs. Thus, meropenem demonstrated greater inhibitory activity than imipenem and activity comparable to that of cefotaxime against these selected strains.
Meropenem (SM-7338) is an investigational carbapenem antibiotic with greater potency than imipenem against many gram-negative bacilli (1, 2, 8) . Because meropenem has demonstrated stability to a variety of ,-lactamases (1, 8) and may have penicillin-binding protein targets different from those of imipenem or cephalosporins (10) , we thought it appropriate to determine the activity of this new agent against a collection of 67 Haemophilus influenzae strains with various levels of susceptibility to ampicillin. These included 19 strains which were ampicillin resistant due to production of 3-lactamase (3 were serotype b), 8 ampicillinresistant, P-lactamase-negative strains (ampicillin MIC . 4 ,ug/ml; 1 was serotype b) (4), and 40 strains which were susceptible to ampicillin (MIC c 1 p.g/ml; 4 were serotype b).
Broth microdilution MICs were determined for all strains according to the methods advocated by the National Committee for Clinical Laboratory Standards (7). Specifically, Haemophilus Test Medium broth (3) was used to prepare twofold-concentration increments of meropenem plus five other beta-lactam antibiotics in microdilution trays (100 ,ul per well). The final inoculum size employed was ca. 5 x 105 CFU/ml, and tests were incubated for 20 to 24 h at 35°C in ambient air. H. influenzae ATCC 49247 was used as a control organism (7) .
MBCs were determined for a subset of 15 strains (5 from each of the three categories of susceptibility or resistance to ampicillin) by subculture of 0.01-ml aliquots of broth with the MICs and supra-MICs from the microdilution trays onto enriched chocolate agar plates incubated in 5% CO2. The MBC was defined by a 99.9% inoculum reduction determined using rejection value tables for a single sample and a 5% error rate (6, 9) . Kinetic time-kill curve assays (6) were performed on a subset of the strains used for the MBC tests. Concentrations of the antibiotics equivalent to the microdilution MIC, as well as two and four times the MIC, were tested in 30-ml volumes of Haemophilus Test Medium broth using an inoculum of 0.5 x 106 to 1 x 106 CFU/ml. Aliquots of the antibiotic-containing and antibiotic-free control broths were removed initially and after 4 and 24 h of incubation at 35°C for plate counts on enriched chocolate agar incubated * Corresponding author.
in 5% CO2. The lower detection limit by this method was 10 CFU/ml based upon a subculture volume of 0.1 ml spread over the surface of a 100-mm-diameter enriched chocolate agar plate. Lack of significant antibiotic carry-over effect was demonstrated by comparing plate counts of the strains at inocula of approximately 102 to 103 CFU/ml in antibioticfree Haemophilus Test Medium broth and counts in broth containing the antibiotic concentrations used for the kinetic kill studies.
Meropenem was highly active against all H. influenzae strains examined in this study, including those resistant to ampicillin irrespective of whether or not they produced ,-lactamase (Table 1) . Meropenem was more active than imipenem against all strains except three of the eight ampicillin-resistant, P-lactamase-negative strains, against which the two carbapenems showed similar activities (Table 1) .
With the exception of ampicillin MICs for the P-lactamaseproducing strains, the MICs of all of the other beta-lactams were highest with the eight ampicillin-resistant, P-lactamasenegative strains. The amoxicillin-clavulanate MICs for those strains ranged from 2 to >16 ,ug/ml, and the cefuroxime MICs ranged from 4 to 64 p.g/ml (Table 1) .
Overall, meropenem was 8-to 32-fold more active than imipenem against the study strains, e.g., the meropenem MIC for 50% of strains (MIC50) was 0.03 ,ug/ml and the MIC for 90% of strains (MIC90) was 0.125 ,ug/ml, in contrast to the imipenem MIC50 and MIC%0 of 1 ,ug/ml (data not shown).
The activity of meropenem was most similar to that of cefotaxime for the strains included in this study.
Meropenem MICs for the H. influenzae ATCC 49247 control strain (which is also ampicillin resistant but does not produce P-lactamase) recommended by the National Committee for Clinical Laboratory Standards (6) ranged from 0.125 to 0.5 ,g/ml, with a modal value of 0.25 ,ug/ml, based on tests performed on 10 separate days.
On the basis of broth microdilution MBC tests, meropenem was bactericidal against 12 of 15 strains tested at the MIC or twice the MIC and was similar in that regard to the other beta-lactams tested for comparison (data not shown). The time-kill assays confirmed the bactericidal effect of meropenem for the test strains irrespective of resistance to ampicillin ( Fig. 1 and 2) . Interestingly, all of the drugs were bactericidal (usually within twice the MIC) against the ampicillin-resistant, 13-lactamase-negative strains when the Ampicillin resistant, 3-lactamase negative bactericidal activities were indexed to the higher MICs for those strains (data not depicted). Similar findings of bactericidal effects of various other beta-lactams against ampicillin-resistant, P-lactamase-negative strains have been reported (5).
In summary, meropenem was highly active against the H.
influenzae strains examined in this study irrespective of the presence of ampicillin resistance mechanisms. If favorable pharmacokinetic properties can be demonstrated with meropenem (e.g., good cerebrospinal fluid penetration), clinical trials of therapy for serious Haemophilus infections would seem to be warranted.
